Aisling Capital, a NYC-based late-stage life sciences investment firm that partners with companies to bring novel medical therapies to market, closed its newest fund, at $280m.
The new fund will allow Aisling Capital to continue to back clinical stage ventures in order improve global health by rapidly bringing breakthrough medical treatments to market.
Read Complete Article